Hyperway

Established in 2019 and based in Chengdu, China, Hyperway is a biopharmaceutical company that focuses on the research and development of innovative and generic drugs. The company has won the 2021 Chengdu New Economy Hundred Key Cultivation Enterprises, Chengdu New Economy Double Hundred Enterprises, and so on. In March 2024, it signed a global development and licensing strategic cooperation agreement with Tengchuang Biotechnology and raised series A+ funding for nearly CNY 100 million in April. As of  2024, the team has more than 100 employees, with R&D personnel accounting for over 80%.

The founder and chairman of the board, Yingfu Li has nearly 30 years of experience in drug discovery and management and served as Deputy General Manager, General Manager, and Group Vice President of ChemPartner.   Hyperway is committed to the research and development of innovative drugs. It has built a technology platform for the development and evaluation of brain-penetrating drugs, including molecular design, molecular synthesis and screening, pharmacokinetic evaluation, and toxicology research. The innovative drug research and development pipeline covers multiple treatment fields such as tumor resistance, tumor immunity, central nervous system, etc.

The innovative products include HBW-3220, HBW-004285, and HBW-012. The company generates revenue by providing innovative drugs. The company will use the funds for the clinical studies of three innovative drugs, HBW-3220, HBW-3210, and HBW-004285, as well as the advancement of multiple preclinical innovative drug development pipelines.